Bio-Rad Laboratories, Inc. (NYSE:BIO) VP James R. Stark sold 1,299 shares of Bio-Rad Laboratories stock in a transaction on Wednesday, November 9th. The stock was sold at an average price of $171.42, for a total value of $222,674.58. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 166.70 on Monday. The stock has a 50 day moving average price of $162.77 and a 200-day moving average price of $151.55. Bio-Rad Laboratories, Inc. has a 12-month low of $122.03 and a 12-month high of $174.02. The firm has a market capitalization of $4.92 billion, a PE ratio of 50.15 and a beta of 0.88.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings results on Tuesday, November 1st. The company reported $0.62 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.11. The business had revenue of $508.75 million for the quarter, compared to analysts’ expectations of $480.60 million. Bio-Rad Laboratories had a return on equity of 3.79% and a net margin of 4.75%. The business’s quarterly revenue was up 8.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.59 EPS. On average, equities research analysts forecast that Bio-Rad Laboratories, Inc. will post $2.77 EPS for the current year.

Several hedge funds have recently made changes to their positions in the company. Emerald Acquisition Ltd. bought a new stake in shares of Bio-Rad Laboratories during the second quarter worth $61,903,000. Morgan Stanley raised its position in shares of Bio-Rad Laboratories by 189.2% in the third quarter. Morgan Stanley now owns 458,276 shares of the company’s stock worth $75,070,000 after buying an additional 299,804 shares during the period. Credit Suisse AG raised its position in shares of Bio-Rad Laboratories by 165.0% in the second quarter. Credit Suisse AG now owns 232,758 shares of the company’s stock worth $33,289,000 after buying an additional 144,933 shares during the period. EverPoint Asset Management LLC acquired a new position in shares of Bio-Rad Laboratories during the second quarter worth about $10,011,000. Finally, First Trust Advisors LP raised its position in shares of Bio-Rad Laboratories by 137.4% in the second quarter. First Trust Advisors LP now owns 113,660 shares of the company’s stock worth $16,256,000 after buying an additional 65,785 shares during the period. Institutional investors and hedge funds own 62.72% of the company’s stock.

Several equities analysts recently issued reports on the company. Zacks Investment Research raised Bio-Rad Laboratories from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 8th. CL King assumed coverage on Bio-Rad Laboratories in a report on Wednesday, October 12th. They set a “buy” rating and a $180.00 price objective for the company. Finally, Jefferies Group lifted their price objective on Bio-Rad Laboratories from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, September 7th.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

5 Day Chart for NYSE:BIO

Receive News & Stock Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related stocks with our FREE daily email newsletter.